Long-term triamcinolone acetonide aerosol treatment in adult patients with chronic bronchial asthma.
Eighty percent of 26 steroid-dependent, chronically asthmatic adults eliminated oral steroid dosage after 12 weeks of treatment with triamcinolone acetonide aerosol (800 micrograms/day). After one year of treatment 60% of the patient were free of oral steroids. Pulmonary function (FEV1, FVC and FEF25-75%) and plasma cortisol test results showed significant improvement during treatment. Adverse effects were mild to moderate.
D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D001314:Auscultation; D001769:Blood; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D006854:Hydrocortisone; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010817:Physician-Patient Relations; D011241:Prednisone / Q000627:therapeutic use; D013902:Radiography, Thoracic; D012129:Respiratory Function Tests; D013375:Substance Withdrawal Syndrome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D000336:Aerosols; D014222:Triamcinolone Acetonide; D011241:Prednisone; D006854:Hydrocortisone